The determinants of stroke phenotypes were different from the predictors (CHADS2 and CHA2DS2-VASc) of stroke in patients with atrial fibrillation: a comprehensive approach

  • Semi Oh1,

    Affiliated with

    • Suk Jae Kim1,

      Affiliated with

      • Soo-Kyoung Ryu1,

        Affiliated with

        • Gyeong-Moon Kim1,

          Affiliated with

          • Chin Sang Chung1,

            Affiliated with

            • Kwang Ho Lee1 and

              Affiliated with

              • Oh Young Bang1Email author

                Affiliated with

                BMC Neurology201111:107

                DOI: 10.1186/1471-2377-11-107

                Received: 9 June 2011

                Accepted: 24 August 2011

                Published: 24 August 2011

                Abstract

                Background

                Atrial fibrillation (AF) is a leading cause of fatal ischemic stroke. It was recently reported that international normalized ratio (INR) levels were associated with infarct volumes. However, factors other than INR levels that affect stroke phenotypes are largely unknown. Therefore, we evaluated the determinants of stroke phenotypes (pattern and volume) among patients with AF who were not adequately anticoagulated.

                Methods

                We analyzed data pertaining to consecutive AF patients admitted over a 6-year period with acute MCA territory infarcts. We divided the patients according to DWI (diffusion-weighted imaging) lesion volumes and patterns, and the relationship between stroke predictors (the CHADS2 and CHA2DS2-VASc score), systemic, and local factors and each stroke phenotype were then evaluated.

                Results

                The stroke phenotypes varied among 231 patients (admission INR median 1.06, interquartile range (IQR) 1.00-1.14). Specifically, (1) the DWI lesion volumes ranged from 0.04-338.62 ml (median 11.86 ml; IQR, 3.07-44.20 ml) and (2) 46 patients had a territorial infarct pattern, 118 had a lobar/deep pattern and 67 had a small scattered pattern. Multivariate testing revealed that the CHADS2 and CHA2DS2-VASc score were not related to either stroke phenotype. Additionally, the prior use of antiplatelet agents was not related to the stroke phenotypes. Congestive heart failure and diastolic dysfunction were not associated with stroke phenotypes.

                Conclusions

                The results of this study indicated that the determinants of stroke phenotypes were different from the predictors (i.e., CHADS2 and CHA2DS2-VASc score) of stroke in patients with AF.

                Background

                Atrial fibrillation (AF) affects 3% to 5% of the population older than 65 years of age [1] and is a leading cause of fatal ischemic stroke [2, 3]. Stroke in patients with AF is generally more severe and the outcome is markedly poorer than in patients with sinus rhythm [4]. Adjusted-dose warfarin is highly effective (~60% reduction), and aspirin is modestly effective (~20% reduction) for the prevention of stroke in AF [5, 6]. Moreover, international normalized ratio (INR) levels at the time of stroke were recently reported to be associated with infarct volumes [7].

                However, the factors affecting stroke phenotypes are unknown among AF patients. Several studies have suggested that infarct patterns are better delineated by DWI than other imaging modalities, are correlated with the underlying stroke pathogenic mechanism,[8, 9] and are associated with stroke outcome [10]. In addition, the infarct pattern on DWI may differ depending on the characteristics (type and nature) of clots [1113]. Risk factors for stroke (the CHADS2 and CHA2DS2-VASc score) and systemic (D-dimer and C-reactive protein) and local (left ventricular ejection fractions) factors may be associated with stroke phenotype. AF is associated with higher levels of prothrombotic factors, endothelial dysfunction, and markers of platelet activation [12, 14, 15]. The formation of left atrial appendage thrombi in AF is influenced by several hemodynamic factors that promote stasis, each of which can fluctuate over time, and perhaps also by mild prothrombotic hematological perturbations that favour thrombosis [6]. Therefore, we evaluated the determinants of stroke phenotypes (i.e., volume and pattern) among patients with AF who were not adequately anticoagulated (INR < 1.6) to identify factors besides the INR level that may influence the phenotypic presentation of stroke. The results presented here could lead to strategies for the prediction of stroke extent and improve clinical outcomes.

                Methods

                Patient selection

                We analyzed demographic, clinical, laboratory, and radiographic data collected prospectively from consecutive patients admitted to Samsung Medical Centre for acute cerebral infarction from January 2005 through June 2011. Inclusion criteria for this study were: (a) presentation within three days of the onset of symptoms, (b) acute ischemic lesions within the MCA distribution on diffusion-weighted imaging (DWI), and (c) AF diagnosed previously or detected during the admission period. The exclusion criteria were: (a) patients who met the Trial of Org 10172 in the Acute Stroke Treatment algorithm competing diagnosis of large artery disease, small vessel, or other causes, (b) patients who did not have INR determination and DWI performed within 12 hours of initial presentation, and (c) patients who had INR levels greater than 1.6 (achieving INRs distributed equally in the range of 1.6 to 2.5 has been reported to provide 90% of the protection of INRs between 2.0 and 3.0 for primary prevention of stroke in patients with nonvalvular AF) [6]. The local Institutional Review Board approved the study and informed consent was obtained from participants.

                Work-up

                All patients underwent MRI (3.0T, Achieva, Philips Medical Systems) using a protocol that also included DWI, gradient-recalled echo, fluid-attenuated inversion recovery, and magnetic resonance angiography (MRA) imaging of the cervical and intracranial vessels [16].

                Variables that could potentially affect the acute infarct volume were recorded for each patient. These included sex, age, prior history of hypertension, diabetes, hyperlipidemia, valvular heart disease, coronary heart disease, time from symptom onset to MRI, and medications used before the onset of stroke including the statins, angiotensin receptor blockers, antiplatelet agent and warfarin. The CHADS2 score,[17] which is a simple method of estimating the risk of stroke in patients with non-rheumatic AF, was estimated from the clinical data and modified to correlate the score with stroke phenotype. Five risk factors are considered when determining the CHADS2 score: (a) C, recent congestive heart failure, (b) H, hypertension, (c) A, age ≥ 75 years, (d) D, diabetes mellitus, and (e) S, history of stroke or transient ischemic attack. In the present study, we used prior stroke or transient ischemic attack instead of the stroke index. In addition, we investigated use of the new CHA2DS2-VASc [18] score system for predicting the stroke phenotype, including additional stroke risk factors: (f) V, indicates vascular disease, (g) A, indicates age between 65-74 and (h) S, indicates sex category(female). The National Institutes of Health Stroke Scale (NIHSS) score on admission was also used to assess the severity of stroke. Stroke onset time was defined as the last time the patient was known to be free of symptoms. All patients underwent routine blood tests and high-sensitivity C-reactive protein (CRP) was taken as the impending cerebrovascular marker [19, 20]. Hemostatic markers of prothrombotic tendency, including D-dimer and fibrinogen, were also evaluated. Patients underwent electrocardiography and cardiac telemetry for at least 24 hours to evaluate the persistence of AF. Paroxysmal AF is defined as intermittent periods of AF interposed with episodes of normal sinus rhythm, normally < 7 days [21]. In addition, echocardiogram was conducted in all but 12 patients who showed poor cooperation or acute illness owing to medical conditions or the stroke itself. During the echocardiogram, the size of the left atrium and left ventricular ejection fraction were measured,[2225] and the E/e' ratio and DT were measured to diagnose the diastolic dysfunction [26].

                DWI Infarct volume measurement: Methods and Image Analysis

                DWI was obtained using two levels of diffusion sensitization (b values of 0 and 1000 s/mm2; 5-7 mm slice thickness; no gap). For each patient, the DWI lesion volumes were automatically outlined with subsequent manual corrections. The volumes were calculated using a computer-assisted volumetric analysis program (Medical Image Processing, Analysis and Visualization, Version 3.0, National Institutes of Health, Bethesda, Md). Raters outlined regions of acute diffusion abnormality on the b = 1000 s/mm2 image while consulting the apparent diffusion coefficient and FLAIR sequences to distinguish acute from nonacute changes in diffusion. All acute DWI lesions were defined on a slice-by-slice basis using a semiautomatic threshold approach by a rater who was blinded to all clinical information.

                Infarct patterns

                We divided the patients into three infarct topography pattern groups based on the observed DWI patterns: (a) territorial infarcts involving two or three MCA subdivisions (superior, inferior, or deep), (b) lobar infarcts involving one subdivision, large deep infarcts, and mixed cortical and deep infarcts, and (c) small (< 1 cm in diameter) scattered patterns, suggesting microembolism. Two readers blinded to the clinical data analyzed the DWI data, and the interobserver agreement (κ-value) was 0.92 (P < 0.001) for interpretation of the DWI lesion pattern (territory vs. lobar/deep vs. small scattered). The opinion of a third reader was obtained in cases of disagreement.

                Statistical analysis

                All numeric data are presented as the mean ± SD or median (interquartile range [IQR]). The differences in DWI pattern and infarct volume and the clinical and laboratory parameters were evaluated by one-way ANOVA with post hoc analysis using the Fisher's least-square difference or Kruskall-Wallis test for continuous variables and Pearson's χ2, Fisher's exact test or linear by linear association for categorical variables. An independent t-test or the Mann-Whitney U test was used to evaluate differences in the factors between the groups. The agreement rate and κ-value between the infarct patterns reported by inter-observers was also obtained. Moreover, multivariate logistic regression analysis (stepwise method) was conducted to predict the independent contribution of factors that influenced stroke phenotypes (territorial pattern or highest quartile DWI lesion volumes). Variables from univariate analyses at P < 0.05 were considered to represent the explanatory variables and the other variables that we were specifically interested in; age, CHADS2 and CHA2DS2-VASc score and PT were entered for multivariate analysis. Among males in the present study, there were 29 current smokers and 24 ex smokers; however, there were only 2 female smokers and no female ex smokers. Accordingly, we did not analyze the impact of smoking on stroke phenotypes. P values < 0.05 were considered to be statistically significant.

                Results

                Among 275 patients who met the inclusion criteria during the study period, only 27 (9.8%) had appropriate anticoagulation as indicated by an INR above 1.6 [6]. Finally, a total of 231 patients (118 men and 113 women; age, 70.0 ± 11.1 years) were included in this study. Reasons for exclusion of the remainder of the patients included probable other etiologies, the presence of large artery disease such as significant stenosis on ipsilateral carotid bifurcation (ten patients) and other causes (seven patients).

                MRIs were completed within an average of 20.0 ± 28.9 hours of the event (range, 1-72 hours). The DWI lesion volumes ranged from 0.04-338.6 ml (median -11.86 ml; IQR, 3.07-44.20 ml). The clinical characteristics of the patients according to the DWI infarct volume quartile and infarct patterns are shown in Tables 1 and 2. NIHSS upon admission was associated with the subgroups of stroke phenotypes (P < 0.001). No correlation was observed between the levels of INR and DWI lesion volumes (r = -0.058, P = 0.495) (Additional file 1).
                Table 1

                Demographic and clinical characteristics among the infarct volume quartile groups

                 

                Quartile of DWI lesion volumes, ml

                P

                 

                Q1

                (< 3.1)

                n = 58

                Q2

                (3.1-11.8)

                n = 58

                Q3

                (11.9-44.2)

                n = 58

                Q4

                (> 44.2)

                n = 57

                (Q4 vs. others)

                NISS score on admission

                4.0 ± 3.9

                8.1 ± 6.1

                10.8 ± 6.5

                15.1 ± 6.8

                < 0.001

                Vascular risk factors

                     

                   Age

                69.0 ± 10.9

                70.0 ± 11.1

                72.5 ± 10.4

                69.5 ± 11.7

                0.547

                   Male gender

                24(41.4%)

                26(44.8%)

                32(55.2%)

                36(63.2%)

                0.036

                Hypertension

                41(70.7%)

                41(70.7%)

                42(72.4%)

                36(63.2%)

                0.250

                   Diabetes

                10(17.2%)

                13(22.4%)

                7(12.1%)

                14(24.6%)

                0.222

                   Previous TIA/stroke

                18(31.0%)

                15(25.9%)

                13(22.4%)

                13(22.8%)

                0.585

                CHADS2*score

                    

                0.871

                0-1

                28(48.3.%)

                24(41.4%)

                25(43.1%)

                25(43.9%)

                 

                2-3

                22(37.9%)

                27(6.6%)

                28(48.3%)

                24(42.1%)

                 

                4-5

                8(13.8%)

                7(12.1%)

                5(8.6%)

                8(14.0%)

                 

                Dysrhythmia

                     

                Paroxysmal atrial fibrillation

                22(37.9%)

                22(37.9%)

                20(34.5%)

                18(31.6%)

                0.476

                Concomitant valvular heart disease

                5(8.8%)

                9(15.5%)

                5(8.6%)

                5(8.9%)

                0.663

                Heart rate (/min)

                78.1 ± 19.2

                82.9 ± 21.6

                85.1 ± 21.4

                84.2 ± 23.2

                0.480

                Medications prior to onset

                     

                Antiplatelet agents user

                26(45.6%)

                20(34.5%)

                26(47.3%)

                19(33.3%)

                0.229

                Warfarin user

                7(12.1%)

                9(15.5%)

                4(6.9%)

                8(14.0%)

                0.610

                Laboratory findings

                     

                D-dimer, mg/dL

                1.51 ± 2.85

                2.01 ± 3.31

                3.45 ± 12.87

                2.06 ± 3.35

                0.035

                Fibrinogen, mg/dL

                320.0 ± 83.9

                303.0 ± 79.2

                335.5 ± 81.9

                346.6 ± 100.2

                0.122

                C-reactive protein, mg/dL

                1.13 ± 2.95

                0.69 ± 1.78

                0.95 ± 2.04

                0.80 ± 1.31

                0.068

                Prothrombin Time, INR

                1.07 ± 0.11

                1.10 ± 0.12

                1.06 ± 0.11

                1.06 ± 0.10

                0.373

                Transthoracic echocardiogram finding

                     

                Left ventricular ejection fraction, %

                62.1 ± 9.8

                59.7 ± 12.4

                60.2 ± 8.5

                56.1 ± 15.4

                0.020

                Left atrium size, ml

                48.0 ± 8.8

                46.5 ± 9.4

                47.8 ± 8.6

                46.5 ± 7.2

                0.660

                E/e' ratio

                13.20 ± 6.25

                16.76 ± 9.85

                13.84 ± 8.06

                14.52 ± 9.00

                0.839

                DT, ms

                230.5 ± 153.6

                248.3 ± 154.5

                207.3 ± 115.8

                216.1 ± 114.2

                0.925

                *In CHADS2, S indicates prior stroke or transient ischemic attack

                Table 2

                Demographic and clinical characteristics among infarct pattern groups

                 

                DWI lesion patterns

                P

                 

                Territory

                n = 46 (19.9%)

                Lobar/Deep

                n = 118 (51.1%)

                Small scattered

                n = 67 (29.0%)

                (Territory vs. others)

                NIHSS score on admission

                16.3 ± 6.3

                9.6 ± 6.1

                4.1 ± 4.2

                < 0.001

                Vascular risk factors

                    

                   Age

                68.3 ± .12.4

                71.6 ± 11.4

                69.3 ± 9.3

                0.324

                Male gender

                29(63.0%)

                57(48.3%)

                32(47.8%)

                0.070

                   Hypertension

                28(60.9%)

                84(71.2%)

                48(71.6%)

                0.733

                   Diabetes

                10(21.7%)

                20(16.9%)

                14(20.9%)

                0.603

                   Previous TIA/stroke

                13(28.3%)

                25(21.2%)

                21(31.3%)

                0.636

                CHADS2*score

                   

                0.684

                0-1

                21(45.7%)

                51(43.2%)

                30(44.8%)

                 

                2-3

                18(39.1%)

                55(46.6%)

                28(41.8%)

                 

                4-5

                7(15.2%)

                12(10.2%)

                9(13.4%)

                 

                Dysrhythmia

                    

                Paroxysmal atrial fibrillation

                15(32.6%)

                44(37.3%)

                23(34.3%)

                0.647

                Concomitant valvular heart disease

                5(11.1%)

                14(12.0%)

                5(7.5%)

                0.878

                Heart rate (/min)

                84.2 ± 25.1

                84.2 ± 21.0

                79.8 ± 19.9

                0.501

                Medications prior to onset

                    

                Antiplatelet agents user

                15(32.6%)

                45(39.1%)

                31(47.0%)

                0.246

                Warfarin user

                8(17.4%)

                12(10.2%)

                8(11.9.%)

                0.221

                Laboratory findings

                    

                D-dimer, mg/dL

                2.37 ± 3.76

                1.89 ± 3.19

                1.29 ± 2.03

                0.105

                Fibrinogen, mg/dL

                340.72 ± 100.6

                324.5 ± 88.0

                319.4 ± 77.7

                0.230

                C-reactive protein, mg/dL

                0.84 ± 1.14

                0.93 ± 2.22

                0.87 ± 2.41

                0.041

                Prothrombin Time, INR

                1.08 ± 0.11

                1.07 ± 0.12

                1.08 ± 0.10

                0.667

                Transthoracic echocardiogram finding

                    

                Left ventricular ejection fraction, %

                55.6 ± 16.3

                60.0 ± 10.2

                61.1 ± 11.1

                0.008

                Left atrium size, ml

                47.2 ± 7.5

                47.8 ± 9.2

                46.4 ± 8.1

                0.991

                E/e' ratio

                14.53 ± 10.21

                15.11 ± 9.00

                13.71. ± 6.16

                0.478

                DT, ms

                237.4 ± 131.9

                215.9 ± 118.9

                244.8 ± 163.3

                0.317

                *In CHADS2, S indicates prior stroke or transient ischemic attack

                The vascular risk factor profiles, the CHADS2 and CHA2DS2-VASc score, had no relationship with either stroke phenotype (Figure 1). Eighty-two patients (35.5%) had paroxysmal AF and the others had permanent AF. Twenty-eight patients were taking warfarin at sub-therapeutic levels, while 91 (39.3%) were taking antiplatelet agents. Interestingly, the prior use of medications including antiplatelet agents and warfarin was not related to the stroke phenotypes. We investigated the use of statin and angiotensin receptor blockers (ARBs), but data was not available for about 30% of the patients and the rest the proportion of the patients who had statins and ARBs was checked only 14.0%-24.1% and 18.5%-35.7%. Therefore, we could not evaluate the relationship between that medications and the stroke phenotype.
                http://static-content.springer.com/image/art%3A10.1186%2F1471-2377-11-107/MediaObjects/12883_2011_509_Fig1_HTML.jpg
                Figure 1

                The association of (A) infarct volume and (B) pattern with CHADS 2 score and (C), (D) CHA 2 DS 2 -VASc score.

                Compared with female, male gender was significantly associated with large infarct volumes (p = 0.036). Additionally, both systemic and local factors were associated with stroke phenotypes. Specifically, the lower left ventricular ejection fraction (p = 0.020) and higher D-dimer (p = 0.035) in patients was significantly associated with the highest quartile group of the DWI lesion volume, and the lower left ventricular ejection fraction was observed in patients with a territorial pattern (p = 0.008). Other variables showed no relationship with stroke phenotypes. Multiple logistic regression analysis was conducted to further evaluate the independent predictors for stroke phenotypes; however, systemic, local factors and CHADS2 and CHA2DS2-VASc score did not significantly add value of either stroke phenotype. (Additional file 2, Table S1 and S2).

                Discussion

                Stroke affects not only the person who may be disabled, but their entire family and other caregivers [27]. In addition, more than half of the individuals at risk of stroke view a major stroke as being worse than death [27, 28]. Identification of predictors of stroke phenotype and modification of these factors are particularly important in patients with AF. Despite recent advances in predicting the occurrence of AF-related stroke, little is known about the determinants of stroke phenotype in this type of ischemic stroke.

                It was recently reported that the admission INR in preadmission warfarin users was inversely correlated with infarct volume as a result of the formation of a more fragile embolus, earlier recanalization or acceleration of thrombolysis [7]. In the present study, only 27 (9.8%) of 275 patients had appropriate anticoagulation as indicated by an INR above 1.6 [6]. Because of that small number and since we wanted to identify factors in addition to INR level that may influence the phenotypic presentation of stroke, we focused on patients who showed inadequate anticoagulation. The results of our study indicated that INR levels below the therapeutic range (< 1.6) were not correlated with infarct volumes, suggesting that only the therapeutic range of anticoagulation can modify the occurrence of stroke and phenotype in patients with AF [29]. In the present study, 91 (39.3%) patients were taking antiplatelet agents before admission. The use of antiplatelet agents before admission was also not related to the stroke phenotypes in the present study.

                We next investigated the association of well-known risk factors for ischemic stroke and stroke phenotypes in patients with AF. Among the patients with AF, the absolute risk of stroke varies depending on patient age and other clinical features (associated stroke risk factors). The CHADS2 score, which is the clinical prediction rule for estimating the risk of stroke in patients with nonrheumatic AF, is the risk stratification scheme most widely used to predict AF-related thromboembolism [17]. In the present study, the CHADS2 and newly revised CHA2DS2-VASc score were not related to the stroke phenotype. Moreover, none of the CHADS2 components (e.g. hypertension and congestive heart failure) were associated with the stroke phenotype. Therefore, the results of the present study may indicate that the stroke phenotypes differed among patients with AF-related stroke, and that the factors related to the severity of stroke must be different from the known factors that contribute to the risk of stroke in AF.

                Finally, local and systemic factors may also contribute to stroke phenotype in AF patients. The thrombi in AF patients have been strongly and consistently linked to stasis. Specifically, reduced blood flow velocities in the left atrial appendage (LAA) increase the duration of blood stasis in the LAA [6]. Recently, increased diastolic filling pressure has been found to be associated with a higher rate of left atrial thrombus in the AF, and these effects occur partially through blood stasis or impaired LAA function [30]. However, in the present study, the left atrial size, left ventricular dysfunction, diastolic dysfunction and the persistence of AF were not independently associated with stroke phenotypes. In addition to local factors (altered flow patterns in the LAA), hypercoagulable state, endothelial damage or inflammation, and platelet activation may all contribute to thrombus formation in AF [3136]. In the present study, univariate analysis revealed that higher D-dimer (a degradation product of fibrinogen) levels were present in patients with territorial patterns. These findings reflect factors associated with thrombin-mediated fibrin formation and indicate that degradation of fibrinogen may be related to thrombus characteristics (size and fragility).

                Strengths of this study included the consecutive recruitment of a well-phenotyped group of patients who underwent comprehensive workups, including various serological markers and echocardiogram. However, the results of this study should be interpreted with caution owing to the modest sample size and because all data were from a single centre. Moreover, endothelial activation and platelet activation were not assessed in this study. Additionally, TEE was only conducted in ten patients, while the other patients showed poor cooperation or acute illness due to medical conditions or the stroke itself.

                Conclusion

                Our data showed that the determinants of stroke phenotypes were different from the predictors of stroke (i.e., CHADS2 and CHA2DS2-VASc risk scheme) in patients with AF who were inadequately anticoagulated. Further studies of different populations and larger cohorts are warranted.

                Declarations

                Acknowledgements

                This study was supported by the Korean Healthcare Technology R&D Project, Ministry of Health & Welfare (A110208) and CRS110-13-1

                Authors’ Affiliations

                (1)
                Department of Neurology, Stroke and Cerebrovascular Centre, Samsung Medical Centre, Sungkyunkwan University

                References

                1. Crystal E, Connolly SJ: Role of oral anticoagulation in management of atrial fibrillation. Heart 2004,90(7):813–817.PubMedView Article
                2. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB: Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996,27(10):1760–1764.PubMedView Article
                3. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991,22(8):983–988.PubMedView Article
                4. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS: Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996,27(10):1765–1769.PubMedView Article
                5. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999,131(7):492–501.PubMed
                6. Hart RG, Halperin JL: Atrial fibrillation and stroke: concepts and controversies. Stroke 2001,32(3):803–808.PubMedView Article
                7. Ay H, Arsava EM, Gungor L, Greer D, Singhal AB, Furie KL, Koroshetz WJ, Sorensen AG: Admission international normalized ratio and acute infarct volume in ischemic stroke. Ann Neurol 2008,64(5):499–506.PubMedView Article
                8. Baird AE, Lovblad KO, Schlaug G, Edelman RR, Warach S: Multiple acute stroke syndrome: marker of embolic disease? Neurology 2000,54(3):674–678.PubMed
                9. Bang OY, Ovbiagele B, Liebeskind DS, Restrepo L, Yoon SR, Saver JL: Clinical determinants of infarct pattern subtypes in large vessel atherosclerotic stroke. J Neurol 2009,256(4):591–599.PubMedView Article
                10. Bang OY, Lee PH, Heo KG, Joo US, Yoon SR, Kim SY: Specific DWI lesion patterns predict prognosis after acute ischaemic stroke within the MCA territory. J Neurol Neurosurg Psychiatry 2005,76(9):1222–1228.PubMedView Article
                11. Caplan LR: Brain embolism, revisited. Neurology 1993,43(7):1281–1287.PubMed
                12. Kaireviciute D, Blann AD, Balakrishnan B, Lane DA, Patel JV, Uzdavinys G, Norkunas G, Kalinauskas G, Sirvydis V, Aidietis A, Lip GY: Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb Haemost 104(1):122–127.
                13. Masuda J, Yutani C, Ogata J, Kuriyama Y, Yamaguchi T: Atheromatous embolism in the brain: a clinicopathologic analysis of 15 autopsy cases. Neurology 1994,44(7):1231–1237.PubMed
                14. Freestone B, Chong AY, Nuttall S, Blann AD, Lip GY: Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 2007,132(4):1253–1258.PubMedView Article
                15. Kamath S, Blann AD, Chin BS, Lip GY: Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation. Heart 2003,89(9):1093–1095.PubMedView Article
                16. Kim SJ, Seok JM, Bang OY, Kim GM, Kim KH, Jeon P, Chung CS, Lee KH, Alger JR, Liebeskind DS: MR mismatch profiles in patients with intracranial atherosclerotic stroke: a comprehensive approach comparing stroke subtypes. J Cereb Blood Flow Metab 2009,29(6):1138–1145.PubMedView Article
                17. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001,285(22):2864–2870.PubMedView Article
                18. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, et al.: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31(19):2369–2429.
                19. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR, et al.: C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001,104(24):2886–2891.PubMedView Article
                20. Zotova IV, Zateishchikov DA, Sidorenko BA: [Predictors of intracardiac thrombosis in patients with atrial fibrillation: factors of hemostasis, markers of inflammation, and genetic factors]. Kardiologiia 2007,47(11):46–54.PubMed
                21. Lip GY, Hee FL: Paroxysmal atrial fibrillation. QJM 2001,94(12):665–678.PubMedView Article
                22. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D: Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995,92(4):835–841.PubMed
                23. Di Tullio MR, Sacco RL, Sciacca RR, Homma S: Left atrial size and the risk of ischemic stroke in an ethnically mixed population. Stroke 1999,30(10):2019–2024.PubMedView Article
                24. Ujino K, Barnes ME, Cha SS, Langins AP, Bailey KR, Seward JB, Tsang TS: Two-dimensional echocardiographic methods for assessment of left atrial volume. Am J Cardiol 2006,98(9):1185–1188.PubMedView Article
                25. Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978,58(6):1072–1083.PubMed
                26. Nagarakanti R, Ezekowitz M: Diastolic dysfunction and atrial fibrillation. J Interv Card Electrophysiol 2008,22(2):111–118.PubMedView Article
                27. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL: Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006,37(6):1583–1633.PubMed
                28. Samsa GP, Matchar DB, Goldstein L, Bonito A, Duncan PW, Lipscomb J, Enarson C, Witter D, Venus P, Paul JE, Weinberger M: Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J 1998,136(4 Pt 1):703–713.PubMedView Article
                29. Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK: Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009,40(1):235–240.PubMedView Article
                30. Iwakura K, Okamura A, Koyama Y, Date M, Higuchi Y, Inoue K, Kimura R, Nagai H, Toyoshima Y, Ozawa M, Ito N, Shibuya M, Omiya S, Takagi T, Morisawa D, Fujii K: Effect of elevated left ventricular diastolic filling pressure on the frequency of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Am J Cardiol 107(3):417–422.
                31. Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GD, Beevers DG: Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996,94(3):425–431.PubMed
                32. Nozawa T, Inoue H, Hirai T, Iwasa A, Okumura K, Lee JD, Shimizu A, Hayano M, Yano K: D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 2006,109(1):59–65.PubMedView Article
                33. Li-Saw-Hee FL, Blann AD, Gurney D, Lip GY: Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 2001,22(18):1741–1747.PubMedView Article
                34. Al-Saady NM, Sopher M: Prothrombotic markers in atrial fibrillation: what is new? Eur Heart J 2001,22(18):1635–1639.PubMedView Article
                35. Choudhury A, Chung I, Blann AD, Lip GY: Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. Chest 2007,131(3):809–815.PubMedView Article
                36. Yip HK, Chang LT, Sun CK, Yang CH, Hung WC, Hang CL, Wu CJ, Chua S, Yeh KH, Chang HW: Platelet activation in patients with chronic nonvalvular atrial fibrillation. Int Heart J 2006,47(3):371–379.PubMedView Article
                37. Pre-publication history

                  1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2377/​11/​107/​prepub

                Copyright

                © Oh et al; licensee BioMed Central Ltd. 2011

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.